Meyahealth
HomeGeneticsGenePARK7 gene
Back to Gene
PARK7 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

PARK7 gene

The PARK7 gene provides instructions for making the DJ-1 protein, which helps protect cells from oxidative stress and assists in protein folding.

Normal Function

The PARK7 gene provides instructions for making the DJ-1 protein. This protein is found in many tissues and organs, including the brain. Studies indicate that the DJ-1 protein has several functions, although none are fully understood. One of the protein's functions may be to help protect cells, particularly brain cells, from oxidative stress. Oxidative stress occurs when unstable molecules called free radicals accumulate to levels that can damage or kill cells. Additionally, the DJ-1 protein may serve as a chaperone molecule that helps fold newly produced proteins into the proper 3-dimensional shape and helps refold damaged proteins. Like other chaperone molecules, the DJ-1 protein may assist in delivering selected proteins to proteasomes, which are structures within cells that break down unneeded molecules. Researchers suggest that the DJ-1 protein may also play a role in activities that produce and process RNA, a chemical cousin of DNA.

Health Conditions Related to Genetic Changes

Parkinson's disease

Researchers have identified more than 25 PARK7 gene variants (also called mutations) that can cause Parkinson's disease, a condition characterized by progressive problems with movement and balance. These variants are associated with the early-onset form of the disorder, which begins before age 50. Some PARK7 gene variants lead to an abnormally small DJ-1 protein or change the building blocks (amino acids) used to make the protein. The altered protein is unstable and does not function properly, if at all. Other variants delete a large portion of the PARK7 gene, preventing the production of any functional DJ-1 protein.

It is unclear how loss of functional DJ-1 protein leads to Parkinson's disease. Some studies suggest that PARK7 gene variants disrupt the protein's chaperone function, which leads to a toxic buildup of misfolded or damaged proteins and eventually to cell death. Another possibility is that PARK7 gene variants impair the protein's ability to protect cells from destructive oxidative stress. Nerve cells that make the chemical messenger dopamine are particularly vulnerable to oxidative stress. With diminished protection, free radicals may cause enough damage to kill these nerve cells. Progressive loss of dopamine-producing nerve cells is a characteristic feature of Parkinson's disease. The death of these cells weakens communication between the brain and muscles, and ultimately the brain becomes unable to control muscle movement.

Frequently Asked Questions

Early-onset Parkinson's disease linked to PARK7 mutations often presents with a slower progression and a higher prevalence of dystonia, which involves sustained muscle contractions causing twisting or repetitive movements. Patients may also experience more prominent psychiatric symptoms, such as depression or anxiety, at a younger age compared to those with late-onset idiopathic Parkinson's. While both forms share core motor symptoms like tremor, rigidity, and bradykinesia, the early-onset form typically begins before age 50 and may have a better long-term response to levodopa therapy with fewer motor complications initially.
The DJ-1 protein normally acts as a shield against oxidative stress by neutralizing free radicals that accumulate in cells. When PARK7 mutations lead to a nonfunctional or absent DJ-1 protein, brain cells, particularly dopaminergic neurons in the substantia nigra, become vulnerable to oxidative damage. Additionally, without DJ-1's chaperone activity, misfolded proteins may accumulate and disrupt cellular processes, leading to mitochondrial dysfunction and eventual cell death. This combined failure in antioxidant defense and protein quality control accelerates the neurodegeneration characteristic of Parkinson's disease.
PARK7-related Parkinson's disease is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene, one from each parent, to develop the condition. If both parents are carriers of one mutated copy each, there is a 25 percent chance with each pregnancy that the child will inherit two mutated copies and develop the disease, a 50 percent chance the child will be a carrier like the parents, and a 25 percent chance the child will inherit no mutated copies. Because it is recessive, carriers typically do not show symptoms of Parkinson's disease.
Genetic testing for PARK7 mutations is primarily indicated for individuals with early-onset Parkinson's disease, defined as symptom onset before age 50. While it is theoretically possible for someone with PARK7 mutations to present later, the condition is strongly associated with early onset. Therefore, clinicians typically reserve PARK7 testing for younger patients or those with a strong family history of early-onset disease. For patients with late-onset Parkinson's, other genetic factors or environmental causes are more likely, and testing for PARK7 may not yield a definitive diagnostic explanation.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ